Gilead is pouring significant cash into a startup that’s seen several setbacks over the years while promising a hefty helping of biobucks down the road if it can advance a handful of antiviral candidates.
The partnership with Assembly Biosciences announced Tuesday aims to discover new antiviral treatments for herpesviruses, hepatitis…
Click here to view original post
